CSI Market
Sign In | Register

Meridian Bioscience Inc (VIVO) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access VIVO quarterly Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Meridian Bioscience Inc's cash-generating activities.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Sep 30 2022)
12 Months 		(Sep 30 2021) (Sep 30 2020) (Sep 30 2019) (Sep 30 2018)
Operating Activities
Income42.46
Depreciation & amortization6.60
Amortization of Other Assets9.91
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories5.22
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.00
Share-based Compensation6.90
Income (Loss) from Equity Method Investments0.00
Loss Contingency, Loss in Period10.00
Amortization Of Deferred Contract Costs-
Change In Accounts Receivable Inventory And Prepaid Expenses-
Change In Accounts Payable Accrued Expenses And Income Taxes Payable-
Amortization Of Deferred Instrument Costs-
Income taxes-0.54
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable4.56
Increase (Decrease) in Accounts Payable and Accrued Liabilities1.04
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-1.55
Other Working Capital-2.25
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities82.36
Investing Activities
Capital Expenditures-8.62
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payment Of Acquisition Consideration Holdback-
Proceeds From Radx Grant Off Setting Cost Of Equipment1.25
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired-3.75
Payments to Acquire Equity Method Investments0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-11.12
Financing Activities
Short-term debt Net-35.00
Other borrowing transactions-0.40
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock2.45
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-1.35
Proceeds And Tax Benefits From Exercises Of Stock Options-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations-
Payment Of Government Grant Obligations-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-34.30
Effect of exchange rate on cash flow-5.26
Discontinued operations0.00
Free Cash Flow73.75
Total Cash Flow31.68
4 historic quarters locked

Sign in to unlock the full Meridian Bioscience Inc cash flow history.

Sign In Create Free Account

About Meridian Bioscience Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-23-029272

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License